These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9660926)

  • 1. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
    Byeon IJ; Li J; Ericson K; Selby TL; Tevelev A; Kim HJ; O'Maille P; Tsai MD
    Mol Cell; 1998 Feb; 1(3):421-31. PubMed ID: 9660926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
    Cammett TJ; Luo L; Peng ZY
    J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
    Li J; Poi MJ; Qin D; Selby TL; Byeon IJ; Tsai MD
    Biochemistry; 2000 Feb; 39(4):649-57. PubMed ID: 10651629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of p16INK4a and its interaction with CDK4.
    Yang R; Serrano M; Slater J; Leung E; Koeffler HP
    Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
    Li J; Joo SH; Tsai MD
    Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
    Russo AA; Tong L; Lee JO; Jeffrey PD; Pavletich NP
    Nature; 1998 Sep; 395(6699):237-43. PubMed ID: 9751050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A.
    Li J; Byeon IJ; Ericson K; Poi MJ; O'Maille P; Selby T; Tsai MD
    Biochemistry; 1999 Mar; 38(10):2930-40. PubMed ID: 10074345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.
    Zhao Q; Boschelli F; Caplan AJ; Arndt KT
    J Biol Chem; 2004 Mar; 279(13):12560-4. PubMed ID: 14701845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
    Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
    J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of p16INK4A correlates with Cdk4 association.
    Gump J; Stokoe D; McCormick F
    J Biol Chem; 2003 Feb; 278(9):6619-22. PubMed ID: 12529334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
    Li J; Melvin WS; Tsai MD; Muscarella P
    Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
    Zhang B; Peng ZY
    Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
    Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
    J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG; Buckmire RA; Bessho M; Liu ET
    J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4.
    Suzuki T; Yoshida M
    Leukemia; 1997 Apr; 11 Suppl 3():14-6. PubMed ID: 9209282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4.
    Suzuki T; Kitao S; Matsushime H; Yoshida M
    EMBO J; 1996 Apr; 15(7):1607-14. PubMed ID: 8612584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational effects on the p16INK4a tumor suppressor protein.
    Yang R; Gombart AF; Serrano M; Koeffler HP
    Cancer Res; 1995 Jun; 55(12):2503-6. PubMed ID: 7780957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
    Wölfel T; Hauer M; Schneider J; Serrano M; Wölfel C; Klehmann-Hieb E; De Plaen E; Hankeln T; Meyer zum Büschenfelde KH; Beach D
    Science; 1995 Sep; 269(5228):1281-4. PubMed ID: 7652577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.